How to Buy Sarepta Therapeutics Stock
Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.
Sarepta Therapeutics stock last closed at $20.11, down 2.71% from the previous day, and has increased 8.59% in one year. It has overperformed other stocks in the Biotechnology industry by 0.3 percentage points. Sarepta Therapeutics stock is currently +36.9% from its 52-week low of $14.69, and -20.58% from its 52-week high of $25.32.
As of Sep 18, 2026, there are 105.63M shares of SRPT outstanding. The market value of SRPT is $2.12B. In the last 24 hours, 6.29M SRPT shares were traded.
How to Buy Sarepta Therapeutics Stock
Wondering how to invest in Sarepta Therapeutics stock? Here's how.
- Decide where to buy Sarepta Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Sarepta Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Pick your method of payment and add your info.
- Analyze Sarepta Therapeutics stock: The Sarepta Therapeutics ticker symbol is SRPT. Is Sarepta Therapeutics stock a good investment? Should you buy shares of SRPT? How do SRPT's underlying business fundamentals look? Do top analysts think Sarepta Therapeutics is a good buy? Why has SRPT's stock price moved recently? (Hint: Our stock market research tools can help you understand if SRPT is a good stock to buy).
- Make your SRPT trade: Decide if you will purchase SRPT shares at the current market price or use a limit order to purchase SRPT shares at a particular price.
- Keep tabs on your SRPT investment: Create a watchlist to get live updates on your investment in Sarepta Therapeutics stock.
Step 1: Decide where to buy Sarepta Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy SRPT stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the right brokerage, you'll need to fill out some personal information so you can invest in SRPT stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create your new brokerage account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've filled out your info on the best stock trading app, you need to deposit funds:
Check out the video below to see the process of transferring funds into your investment account.
Step 4: Analyze Sarepta Therapeutics stock
After you have figured out the best place to buy Sarepta Therapeutics stock, it's very important to research their stock before you buy, so you truly understand the risk as well as the opportunity.
Sarepta Therapeutics quick stats
Fundamentals of Sarepta Therapeutics
WallStreetZen was built to help average investors do better fundamental analysis quickly.
You can see all of the due diligence checks on SRPT's stock page.
Is SRPT stock properly valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge SRPT's intrinsic value.
Using relative valuations methods:
- SRPT may be undervalued based on its P/B ratio of 1.39x, relative to Biotechnology industry P/B ratio of 5.28x
You can access additional valuation analysis on SRPT's stock here.
Is SRPT a healthy company?
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the SRPT balance sheet.
- Total SRPT debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the SRPT balance sheet.
Failed Financial Due Diligence Checks:
- SRPT has a relatively high debt to equity ratio of 1.09.
- SRPT's operating cash flow of $111.01M allows it to safely service it's debt of $1.05B.
- SRPT earnings of -$130.92M is not enough to cover its interest payments.
- SRPT profit margin has gone down from -2.3% to -6.9% in the past year.
Is SRPT stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 5 Equities analysts who give forecasts on SRPT, the consensus analyst rating on Sarepta Therapeutics is a Sell
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Sarepta Therapeutics stock forecast page.
SRPT Technical Indicators
SRPT Earnings
Last year, SRPT revenue was $1.97B. During the past five year, SRPT's revenue has increased by 26.89% per year. This was faster than the Biotechnology industry average of 24.78%.
Find out more about SRPT's earnings and revenue performance here.
Latest Insiders Trades at SRPT
Over the last year, insiders at SRPT have sold more shares than they have bought.
Ian Michael Estepan, COO of SRPT, was the latest SRPT insider to sell. They sold $551,033.78 worth of SRPT stock on Sep 4, 2026.
Get more info about who owns SRPT shares here.
Can I get consistent income from SRPT stock?
No, Sarepta Therapeutics doesn't provide an income stream by paying out dividends.
SRPT Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your SRPT trade
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given dollar amount limit, use a limit order.
Click the Open Trade button and eToro will execute your order.
If you need more help buying stocks on eToro, click the how to video below:
Step 6: Keep tabs on your SRPT investment
Now that you own some SRPT shares, you'll want to keep up with your stock purchase.
Start a watchlist to track the most important metrics related to your SRPT stock.
SRPT Feed
How to Buy Stock in Sarepta Therapeutics
To summarize, here are the 6 steps to buy Sarepta Therapeutics stock:
- Decide where to buy Sarepta Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Sarepta Therapeutics stock
- Make your SRPT trade
- Keep tabs on your SRPT investment
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to monitor your new investment in Sarepta Therapeutics, create a watchlist today.
More Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.